Revista: Global & Regional Health Technology Assessment
Resumen: the approval of new non-insulin treatments has broadened the therapeutic arsenal, but it has also increased the complexityof choice for the treatment of type 2 diabetes mellitus (DM2). The objective of this study was to systematically review the literature on economic evaluations associated with non-insulin antidiabetic drugs (NIADs) for DM2. The review included a total of 57 studies, in which 134 comparisons were made between NIADs. Under an acceptability threshold of 25,000 euros per QALY gained, iSLGT-2 were preferable to iDPP-4 and sulfonylureas in terms of incremental cost-utility. By contrast, there were no conclusive comparative results for the other two new NIAD groups (GLP-1 and iDPP-4). The heterogeneity of the studies’ methodologies and results hindered our ability to determine under what specific clinical assumptions some NIADs would be more cost-effective than others. Economic evaluations of healthcare should be used as part of the decision-making process, so multifactorial therapeutic management strategies should be established based on the patients’ clinical characteristics and preferences as principal criteria.
Cómo citar: Zozaya, N., Capel, M., Simón, S., Soto-González, A. (2018, October). A systematic review of economic evaluations in non-insulin antidiabetic treatments for patients with type 2 Diabetes Mellitus. In Value in Health (Vol. 21, pp. S132-S132). STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA: ELSEVIER SCIENCE INC.